Country Information in ICSR: Regulatory Requirements

This blog covers:

1. Key element that related to country information in ICSR processing.
2. How country information influences regulatory reporting and submissions.
3. Why accurate country identification matters, with practical examples.

Introduction

Country information is an important part of Individual Case Safety Report (ICSR) processing. At first glance, recording a country in a safety report may appear straightforward.

However, pharmacovigilance professionals need to understand that different places where country-related data elements serve different regulatory and operational purposes.

So let’s dive in to it.

Following country codes Pharmacovigilance case processing

Every element that follows country information as Alpha-2 codes in all the element.

Purpose	India	United States
ISO 3166-1 alpha-2	IN	US
International telephone calling code	+91	+1

There are in many different instance in case rpocessinf follows countrry details in regualtroy and ICH standrad specific infmration.

For example, the country where an adverse reaction occurred may be different from the country where the reporter is located, where the medicinal product was obtained, or where the product was authorised. Similarly, the organisation transmitting an ICSR may be located in an entirely different country.

These distinctions become particularly important when processing international cases, literature reports, clinical trial cases, and reports involving patients who experience adverse reactions while travelling.

The ICH E2B(R3) implementation guide specifies several country-related data elements and their corresponding requirements. Most of these fields use the two-letter ISO 3166-1 alpha-2 country codes.

Let’s understand how these country details are handled during ICSR processing and why they matter.

Elements that cover country codes in as Pharmacoviglance data element

1.1 Reporter’s Country Code (C.2.r.3)

The reporter is a person who aware of this incident happened/occurred with the particualr person or patinet. So reporter may be HCP, Treating physician, lawyer or consumer.

The Reporter’s Country Code identifies the country associated with the primary source or reporter of the adverse event information.

Practical example:

A healthcare professional based in Germany reports an adverse reaction experienced by a patient while travelling in France.

In this situation, the reporter’s country code should be DE, while the country where the reaction occurred should be FR.

Note: It is important not to populate the reporter’s country based on the patient’s nationality or country of residence.

Regulatory significance: The primary source identified for regulatory purposes is important in determining whether a case is treated as domestic or foreign in the relevant reporting context. The primary source for regulatory purposes is identified separately using C.2.r.5.

1.2 Sender’s Country Code (C.3.4.5)

The Sender’s Country Code identifies the country in which the organisation or individual transmitting the ICSR is located.

This is different from the reporter’s country.

For example:

• Reporter: Healthcare professional in Germany.
  
• Sender: Pharmaceutical company in India.
  
• Country where the reaction occurred: France.
  

The respective country codes would be:

• Reporter’s country: DE
  
• Sender’s country: IN
  
• Country of occurrence: FR
  

This distinction becomes particularly important when pharmaceutical companies receive cases from international affiliates, licensing partners, distributors, or other organisations and subsequently transmit them to regulatory authorities.

1.3 Study Registration Country (C.5.1.r.2)

This data element is relevant to cases originating from clinical trials or other registered studies.

The Study Registration Country identifies the country that assigned the Study Registration Number provided in C.5.1.r.1.

It should not automatically be populated with the country where the study was conducted or where the patient experienced the adverse event.

Example:

A clinical study is registered in the United States, but a participant enrolled in India experiences an adverse event while participating in the study.

The relevant information would be:

• Study Registration Number: The registered study identifier.
  
• Study Registration Country: US.
  
• Country where the reaction occurred: IN, if the event occurred in India.
  

The country code must represent the jurisdiction that assigned the registration number.

1.4 Country Where the Reaction / Event Occurred (E.i.9)

This is one of the most important country-related fields in ICSR processing. It is more regulatory submisison specific.

The country of occurrence identifies the country where the patient actually experienced the adverse reaction or event.

It does not refer to:

• The patient’s country of residence.
  
• The patient’s nationality.
  
• The reporter’s country.
  
• The sender’s country.
  
• The country where the medicinal product was manufactured.
  

Example:

A patient residing in India travels to Germany and experiences an adverse reaction while taking a medicinal product.

A healthcare professional in France subsequently reports the case to a pharmaceutical company located in the United Kingdom.

The country information would be:

Data element	Country
Patient’s country of residence	India
Reporter’s country	France
Sender’s country	United Kingdom
Country where reaction occurred	Germany

The country of occurrence should therefore be DE.

The ICH E2B(R3) implementation guide specifically illustrates a similar scenario involving a patient living in one country, experiencing an event in another country, and reporting through a healthcare professional in a third country.

1.5 Country Where the Drug Was Obtained (G.k.2.4)

This data element captures the country where the medicinal product was obtained.

It is particularly relevant when the product was purchased, dispensed or otherwise supplied in a country different from the patient’s country of residence or the country where the reaction occurred.

Example:

A patient residing in India purchases a medicinal product during a visit to the United Arab Emirates. After returning to India, the patient experiences an adverse reaction.

The country where the drug was obtained is AE, while the country where the reaction occurred is IN.

This information can be useful when investigating:

• Cross-border purchases.
  
• Parallel imports.
  
• Products obtained through online pharmacies.
  
• Products supplied through international distribution channels.
  
• Suspected counterfeit or falsified medicinal products.
  

The country where the drug was obtained should not be assumed from the product’s marketing authorisation country.

1.6 Country of Authorisation / Application (G.k.3.2)

This field identifies the country where the medicinal product was authorised when the relevant case report is transmitted to that country, if known, in the circumstances described by the E2B(R3) guidance.

An important point is that G.k.3.2 is conditional on the availability of the Medicinal Product Identifier (MPID) and the authorisation/application number.

According to the ICH E2B(R3) implementation guide:

• If the MPID is unavailable, G.k.3.1 captures the authorisation or application number.
  
• G.k.3.2 captures the country of authorisation/application.
  
• G.k.3.2 is optional but required if G.k.3.1 is provided.
  

Example:

A medicinal product is authorised in India and is also authorised in the United Kingdom under a separate marketing authorisation.

If the case is being reported to the relevant country and the MPID is unavailable, the applicable authorisation number and country information should be provided as appropriate.

The country of authorisation should not be confused with the country where the drug was obtained.

1.7 Country of Occurrence and Primary Source for Regulatory Purposes

These two concepts are closely related but should not be treated as interchangeable.

The country of occurrence is recorded in E.i.9, whereas C.2.r.5 identifies the primary source for regulatory purposes.

In cases involving multiple reporters, the primary source for regulatory purposes identifies which source should be used for the regulatory classification of the case.

The ICH guidance requires one and only one primary source to be identified for regulatory purposes in an ICSR.

This is particularly important when cases are received from multiple sources, such as:

• Healthcare professionals.
  
• Patients or consumers.
  
• Pharmaceutical companies.
  
• Regulatory authorities.
  
• Published literature.
  
• Clinical investigators.
  

The original primary source should not be replaced merely because another organisation subsequently receives or retransmits the case.

2. Why Is the Country of Occurrence Important?

The country of occurrence provides important geographical context for the adverse event.

It helps pharmacovigilance professionals understand where the event happened and distinguish domestic cases from events that occurred outside a particular jurisdiction.

Some of the important considerations include:

1. Regulatory assessment

Regulatory authorities and marketing authorisation holders may need to evaluate whether a case falls within their reporting responsibilities. Country of occurrence can be relevant to this assessment, alongside the primary source, product authorisation status and applicable regional requirements.

2. Domestic versus foreign case classification

The country of the primary source for regulatory purposes is particularly important when determining whether a case is domestic or foreign in the relevant reporting context. The reporter’s country and primary-source designation should therefore be reviewed carefully.

3. Local pharmacovigilance obligations

Different countries may have their own reporting requirements, submission procedures and timelines. The country information helps determine which local requirements need to be assessed.

4. Signal detection and safety evaluation

Country information can help identify geographical patterns, such as a higher number of reported cases from a particular region or country.

5. Product quality investigations

If multiple cases involving a particular batch or product are reported from a specific country, the information may support further investigation into distribution, storage, manufacturing or product-quality concerns.

6. Cross-border safety monitoring

Cases involving patients who travel internationally or obtain medicines from foreign markets require careful assessment of the different countries involved.

It is important to remember that the country of occurrence alone does not determine whether a case is reportable or whether it qualifies for expedited reporting. The applicable regulatory requirements, seriousness, expectedness, causality, product status and reporting context must also be considered.

3. How Does the Country of Occurrence Influence Regulatory Reporting?

Country information is particularly important when assessing regulatory reporting obligations.

For example, consider a pharmaceutical company holding marketing authorisations in India, the United Kingdom and Germany.

The company receives three reports:

• Case 1: An adverse reaction occurred in India.
  
• Case 2: An adverse reaction occurred in Germany.
  
• Case 3: An adverse reaction occurred in the United Kingdom.
  

Although all three cases are received by the same company, the applicable reporting obligations may differ depending on the product’s authorisation status, the reporting source, the relevant regulatory jurisdiction and the applicable local requirements.

The pharmacovigilance team should therefore evaluate:

1. Where did the reaction occur?
2. Where is the primary source located?
3. Which source has been designated as the primary source for regulatory purposes?
4. Where is the medicinal product authorised?
5. Is the product marketed or distributed in the relevant country?
6. Which regulatory authority needs to receive the report?
7. What are the applicable reporting timelines?
8. Are there additional local reporting or submission requirements?

Important: A case occurring in a particular country does not automatically mean that it must be submitted to that country’s regulatory authority. Reporting obligations must be assessed against the applicable legislation and the organisation’s regulatory responsibilities.

4. How Are Country Codes Used in Case Identification Numbers?

Country information is also relevant when generating unique case identification numbers in E2B(R3).

Two important data elements should be understood:

4.1 Sender’s (Case) Safety Report Unique Identifier (C.1.1)

This identifier uniquely identifies the ICSR assigned by the sender.

According to the ICH E2B(R3) implementation guide, it should contain three segments:

Country code – Company or regulator name – Report number

For example:

FR-ABCPharma-12345

Here:

• FR represents the country code.
  
• ABCPharma represents the company or regulator identifier.
  
• 12345 represents the organisation’s case number.
  

The country code in C.1.1 corresponds to the country of the primary source for regulatory purposes (C.2.r.3), not necessarily the country where the reaction occurred.

The identifier generally remains unchanged when the same sender transmits follow-up information. However, the ICH guide describes certain exceptions, including changes in the primary-source country code or country where the reaction occurred.

4.2 Worldwide Unique Case Identification Number (C.1.8.1)

This identifier is used to identify the case worldwide.

It follows the same general identification format described for C.1.1.

However, an important difference exists:

When a case is retransmitted by another organisation, the retransmitter should assign its own Sender’s Case Safety Report Unique Identifier (C.1.1), but must not change the original Worldwide Unique Case Identification Number (C.1.8.1).

This helps maintain the identity and traceability of the case across different organisations and regulatory authorities.

Practical example:

A pharmaceutical company in France initially receives a case and assigns:

• C.1.1: FR-ABCPharma-12345
  
• C.1.8.1: FR-ABCPharma-12345
  

The case is subsequently transmitted to another organisation in Germany, which retransmits it to a regulatory authority.

The retransmitting organisation may assign its own C.1.1, but the original C.1.8.1 must be retained.

This distinction is essential when managing follow-up reports, duplicate cases and cross-company case exchanges.

5. Understanding the Role of the Marketing Authorisation Holder (MAH)

A Marketing Authorisation Holder (MAH) is the organisation or legal entity that holds the marketing authorisation granted by the competent regulatory authority for a medicinal product.

The MAH is generally responsible for fulfilling applicable pharmacovigilance obligations associated with its authorised medicinal products.

In international pharmacovigilance, the same medicinal product may have different marketing authorisation holders in different countries.

For example:

• Company A holds the marketing authorisation in India.
  
• Company B holds the marketing authorisation in the United Kingdom.
  
• Company C holds the marketing authorisation in Germany.
  

These organisations may be subsidiaries, affiliates, licensing partners or separate legal entities.

The MAH information is relevant to product identification and regulatory reporting, particularly when providing the holder/applicant information in G.k.3.3.

It should not be confused with the sender of the ICSR. The sender is the organisation transmitting the report, whereas the MAH is the organisation holding the relevant marketing authorisation.

6. Practical Example: Understanding Multiple Countries in One ICSR

Consider the following hypothetical scenario:

An Indian patient travels to Germany and purchases a medicinal product from a local pharmacy. The patient experiences a suspected adverse reaction while in Germany. A healthcare professional in France subsequently reports the event to a pharmaceutical company based in the United Kingdom.

The medicinal product is authorised in India and Germany. The report also originates from a registered clinical study whose registration number was assigned in the United States.

The country information may be represented as follows:

Data element	Country	Code
Patient’s country of residence	India	IN
Reporter’s country (C.2.r.3)	France	FR
Sender’s country (C.3.4.5)	United Kingdom	GB
Study registration country (C.5.1.r.2)	United States	US
Country of occurrence (E.i.9)	Germany	DE
Country where drug was obtained (G.k.2.4)	Germany	DE
Country of authorisation/application (G.k.3.2)	As applicable to the reporting context	DE or IN

The country component of C.1.1 would be based on the primary source for regulatory purposes, assumed here to be the French reporter: FR-CompanyName-12345.

This example demonstrates why pharmacovigilance professionals must evaluate each country-related data element independently rather than using one country value across the entire case.

7. Common Mistakes in Country Coding During ICSR Processing

Some common mistakes encountered during case processing include:

1. Populating the reporter’s country based on the patient’s country of residence.
2. Using the sender’s country instead of the reporter’s country.
3. Assuming the country of occurrence is always the reporter’s country.
4. Populating the study registration country based on the country where the clinical trial participant was enrolled.
5. Confusing the country where the medicinal product was obtained with the country where it was authorised.
6. Using telephone calling codes instead of ISO country codes.
7. Incorrectly generating the country component of C.1.1.
8. Changing C.1.8.1 when retransmitting an ICSR.
9. Assuming that the country of occurrence alone determines regulatory reporting obligations.
10. Using an incorrect country code or an outdated internal country-code list.

These errors may result in incorrect case classification, inaccurate regulatory information, data-quality issues or difficulties during electronic transmission.

8. Best Practices for Country-Code Selection During Case Processing

Pharmacovigilance professionals can follow these practices to minimise country-related errors:

• Always refer to the original source documents when identifying the reporter’s country.
  
• Distinguish between the patient’s residence, reporter’s location, sender’s location and country of occurrence.
  
• Use the ISO 3166-1 alpha-2 country-code standard for the relevant E2B(R3) data elements.
  
• Maintain a validated and regularly updated country-code reference list.
  
• Do not automatically populate one country field using another country field.
  
• Verify the primary source designation before generating the case identifier.
  
• Preserve the original Worldwide Unique Case Identification Number during retransmission.
  
• Verify the country of drug authorisation and the country where the product was obtained independently.
  
• Review local regulatory requirements before determining the reporting destination and applicable timeline.
  
• Validate country-related fields during quality control and E2B(R3) XML generation.

Conclusion

Country information is much more than a simple administrative detail in pharmacovigilance. Each country-related data element has a distinct purpose in identifying the origin of the report, the location of the reporter, the geographical occurrence of the adverse reaction, the source of the medicinal product and its marketing authorisation status.

Understanding these differences is particularly important when processing international ICSRs, managing cross-border cases, generating unique case identifiers and assessing regulatory reporting obligations.

For pharmacovigilance professionals, the key principle is simple: never assume that all country-related fields in an ICSR refer to the same country. Each field must be populated according to its specific E2B(R3) definition and the information available in the source documents.